Hygeia Healthcare reported 1H26 revenue of RMB 1.96 billion, down 1.40% year-on-year, while net profit rose 4.70% to RMB 257.44 million. Non-IFRS adjusted net profit increased 1.50% to RMB 266.52 million, supported by a 0.80-percentage-point expansion in gross margin to 27.40%.

Operating indicators advanced: patient visits reached 2.30 million (+4.10%), surgeries climbed to 46,000 (+8.20%) and Level 3-4 surgeries rose 17.80% to roughly 21,000. Free cash flow improved 38.50% to RMB 296.30 million as capital expenditure fell 32.90% to RMB 162.40 million.

The balance sheet strengthened; interest-bearing liabilities declined 7.40% to RMB 2.26 billion, trimming the interest-bearing debt-to-asset ratio by 1.50 percentage points to 21.30%. Cash and equivalents, term and restricted deposits plus financial assets at fair value totalled RMB 759.00 million, up 2.50% from end-2025.

The board approved a three-year shareholder return scheme of up to RMB 1.50 billion (about RMB 500 million per year) through share repurchases and/or dividends. During 1H26 the company repurchased 9.31 million shares for HK$99.76 million; an additional 2.09 million shares were bought in July.

Operationally, Hygeia Healthcare managed or operated 17 oncology-focused hospitals across 13 cities in eight provinces and opened Wuxi Hygeia Hospital in early 2026. A new Class III hospital in Changshu is preparing for inspection prior to launch. Hospital properties are fully self-owned, covering about 1,200 mu of land with capacity for nearly 14,000 beds.

Founder and Chairman Zhu Yiwen increased his personal stake by 3.55 million shares in May 2026, taking cumulative on-market purchases since listing to over 9.60 million shares.

The board declared no interim dividend for the period.